marked.bio

Company

Treeline Biosciences

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

cetuximab 1pembrolizumab 1

Trials

2 of 2 trials shown

  1. TLN-372 in Advanced KRAS Mutant Solid Tumors

    Recruiting Phase 1 Treeline Biosciences Started 2025Primary completion 2031-12 NCT07204340

    TLN-372cetuximabpembrolizumab

    Patients must have locally advanced or metastatic KRAS mutant solid tumors.

    KRAS G12CKRAS G12DKRAS Mutant Solid Tumors

  2. A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

    Active, not recruiting Phase 1 Treeline Biosciences Started 2024Primary completion 2026-11 NCT06733441

    TLN-254

    Anaplastic large-cell lymphoma, Alkaline phosphatase (ALK) positive.

    ALK fusionLymphoma